NSE / BSEHealthcare
β‚Ή1149.75-11.25-0.97%
P/E18.4Mkt Capβ‚Ή99.42 K CrEV/EBITDA14.3

Dr. Reddy's Laboratories Ltd.

P/E18.4Mkt Capβ‚Ή99.42 K CrEV/EBITDA14.3
Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Healthy return on equity of 17.9%

Concerns0

    Rule-based from financial data. Not advice.

    Price Historyβ–Ό 11.62% over 1Y

    Monthly Returns

    Unlock Monthly Returns

    Available on Pro and Institutional plans.

    Sign up free

    Year-to-Date ROI

    Unlock Year-to-Date ROI

    Available on Pro and Institutional plans.

    Sign up free

    Historical Volatility

    Unlock Historical Volatility

    Available on Pro and Institutional plans.

    Sign up free

    Historical Performance

    Revenue, profitability, and cash flow trends (β‚Ή Crores)

    Revenue (10Y)

    Operating Income (10Y)

    Net Profit (10Y)

    Operating Margin % (10Y)

    Dividend Payout % (10Y)

    Free Cash Flow (10Y)

    Growth Summary

    Latest fiscal year: Mar 2025

    Revenueβ‚Ή23.11 K Crβ–² 18.6%
    EBITDA Growthβ€”
    Net Profitβ‚Ή5.35 K Crβ–² 23.2%
    Cash from Ops (CFO)β€”
    Free Cash Flow (FCF)β€”β–² 32.6%
    Revenue CAGR 5Y10.5%
    EBITDA CAGR 5Y13.4%
    Net Profit CAGR 5Y8.1%
    NP Growth 1Y23.2%

    Historical Growth

    Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

    YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
    Mar 2025β‚Ή23.11 K Crβ€”β‚Ή5.35 K Crβ€”β€”18.5%18.6%23.2%
    Mar 2024β‚Ή19.48 K Crβ€”β‚Ή4.34 K Crβ€”β€”17.9%14.9%66.2%
    Mar 2023β‚Ή16.96 K Crβ€”β‚Ή2.61 K Crβ€”β€”12.8%17.8%61.0%
    Mar 2022β‚Ή14.40 K Crβ€”β‚Ή1.62 K Crβ€”β€”8.9%7.9%-25.8%
    Mar 2021β‚Ή13.35 K Crβ€”β‚Ή2.19 K Crβ€”β€”12.9%12.6%-25.6%
    Mar 2020β‚Ή11.85 K Crβ€”β‚Ή2.94 K Crβ€”β€”19.3%11.5%130.1%
    Mar 2019β‚Ή10.63 K Crβ€”β‚Ή1.28 K Crβ€”β€”10.1%13.5%125.2%
    Mar 2018β‚Ή9.36 K Crβ€”β‚Ή567.00 Crβ€”β€”4.8%-3.7%-59.0%
    Mar 2017β‚Ή9.72 K Crβ€”β‚Ή1.38 K Crβ€”β€”11.9%-5.6%0.7%
    Mar 2016β‚Ή10.29 K Crβ€”β‚Ή1.37 K Crβ€”β€”11.4%2.8%-18.2%

    Financial Statements

    Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

    Free plan Β· showing 1 year of data.Upgrade

    Consolidated Figures in USD Millions.

    Unnamed: 0TTM
    Revenue / Net Sales23,006
    Total Expenses16,053
    EBIT / Operating Profit6,953
    OPM %30%
    Other Income1,412
    Finance Costs127
    Depreciation & Amortisation1,104
    Profit Before Tax7,134
    Tax %-
    Net Profit / PAT5,399
    EPS (β‚Ή)64.69
    Dividend Payout %-

    Peer Comparison

    Healthcare sector peers, ranked by market cap

    CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
    Dr. Reddy's Laboratories Ltd.this co.β‚Ή99.42 K Crβ‚Ή23.11 K Cr18.403.1514.3418.6%
    Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
    Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
    Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
    Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
    Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
    Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
    Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

    Learn while you research

    Hand-picked academy chapters to deepen your understanding of Dr. Reddy's Laboratories Ltd. and the metrics that matter.

    Browse the full Equiscale Academy